Anti-Coagulants - Uruguay

Uruguay

Uruguay is expected to witness a significant growth in the Anti-Coagulants market.
By 2024, the projected revenue in this market is estimated to reach US$16.02m.
Furthermore, it is anticipated that the revenue will continue to grow at an annual growth rate (CAGR 2024-2029) of 7.46%, resulting in a market volume of US$22.96m by 2029.
When compared globally, United States is projected to generate the highest revenue in the Anti-Coagulants market, with an estimated value of US$16,740.00m in 2024.
in Uruguay, though smaller in size, is expected to make a considerable contribution to this market.
In Uruguay, the market for anti-coagulants is experiencing a significant growth due to the aging population and increasing prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Uruguay has been steadily developing in recent years.

Customer preferences: Uruguayans are becoming increasingly aware of the importance of preventing and treating cardiovascular diseases, which has led to a higher demand for anti-coagulants. Patients are also more inclined towards using newer and more effective drugs, such as direct oral anticoagulants (DOACs), over traditional warfarin.

Trends in the market: The Anti-Coagulants market in Uruguay is expected to continue growing due to an aging population and an increase in the prevalence of diseases that require anticoagulation therapy. Additionally, the market is likely to see a shift towards DOACs, which offer several advantages over warfarin, including a lower risk of bleeding and fewer drug interactions.

Local special circumstances: Uruguay has a universal healthcare system that provides free healthcare to all citizens, which has helped to increase access to anticoagulation therapy. However, the system is underfunded and faces significant challenges, including a shortage of healthcare professionals and limited resources for new drug approvals.

Underlying macroeconomic factors: Uruguay has experienced steady economic growth in recent years, which has led to an increase in healthcare spending. The government has also implemented several policies to promote the use of generic drugs, which has helped to reduce costs for patients and increase access to healthcare. However, the country still faces significant challenges in terms of healthcare infrastructure and funding.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.